Figure 9 KD Validation in Huh7 cells (Malhi et al., 2007)

Western blot analysis with anti-DR4 antibodies (1139) was performed for DR5 and DR4 expression using whole cell lysates from Huh 7 cells transfected with respective siRNAs. In cells treated with siDR4, a decrease in DR4 level was observed, DR5 levels were unchanged. Scrambled siRNA was used as control.

Figure 8 Immunocytochemistry Validation of DR4 in human melanoma cells (Ekmekcioglu et al., 2008)

MeWo melanoma cells were exposed to affinity-purified MDA7/IL-24. After 48 h of treatment, cells were collected and cytospins prepared for cytochemical assessment of their TRAIL receptor (R1 and R2) expression (anti-DR4 (1139) or anti-DR5, AEC, hematoxylin). Both DR4 and DR5 expression were upregulated in MeWo cells after treatment.

Figure 7 Immunofluorescence Validation of DR4 in rat brain (Cantarella et al., 2014)

DR4 protein expression detected by anti-DR4 antibodies (1139) was increased after transient brain ischemia (tMCAO) and decreased after pre-conditioning stimulus. Confocal microscopic images displaying NeuN (a,d, g) (green), DR4 (b, e, h) (red), and Merge (c, f, i) (yellow) in the brain peri-ischemic region of rats after 5 h.

Figure 6 KD Validation in SW480 cells (Goda et al., 2008)

The expression of DR4 was knocked down via DR4 siRNA, 24 h later
cells were treated with dipyridamole for 24 h. DR4 protein expression detected by anti-DR4 antibodies (1139) was disrupted. Dipyridamole up-regulated the expression of DR4.